Nu Skin Enterprises (NYSE:NUS)‘s stock had its “underperform” rating reiterated by research analysts at Bank of America in a report released on Thursday. They presently have a $65.00 price target on the stock, down from their prior price target of $75.00. Bank of America’s price objective would suggest a potential upside of 4.62% from the company’s current price.
A number of other brokerages have also weighed in on NUS. DA Davidson started coverage on shares of Nu Skin Enterprises in a research note on Tuesday, October 9th. They issued a “buy” rating and a $92.00 price target on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $92.00 price target on shares of Nu Skin Enterprises in a research note on Thursday, November 8th. Zacks Investment Research lowered shares of Nu Skin Enterprises from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 8th. Citigroup set a $88.00 price target on shares of Nu Skin Enterprises and gave the company a “buy” rating in a research note on Thursday, November 8th. Finally, Tigress Financial reaffirmed a “buy” rating on shares of Nu Skin Enterprises in a research note on Wednesday, November 21st. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $83.63.
Nu Skin Enterprises stock traded down $2.70 during midday trading on Thursday, hitting $62.13. 79,232 shares of the stock were exchanged, compared to its average volume of 342,525. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.93 and a quick ratio of 1.25. Nu Skin Enterprises has a 52 week low of $60.60 and a 52 week high of $88.68. The firm has a market capitalization of $3.60 billion, a price-to-earnings ratio of 19.24, a PEG ratio of 1.64 and a beta of 0.99.
Nu Skin Enterprises (NYSE:NUS) last announced its quarterly earnings results on Wednesday, November 7th. The company reported $0.94 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.96 by ($0.02). Nu Skin Enterprises had a net margin of 5.93% and a return on equity of 27.50%. The company had revenue of $675.31 million during the quarter, compared to the consensus estimate of $664.99 million. During the same period in the previous year, the firm posted $0.76 EPS. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. As a group, analysts predict that Nu Skin Enterprises will post 3.51 EPS for the current fiscal year.
In other news, General Counsel D Matthew Dorny sold 2,500 shares of Nu Skin Enterprises stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $82.18, for a total value of $205,450.00. Following the sale, the general counsel now directly owns 33,871 shares in the company, valued at $2,783,518.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 7,500 shares of company stock worth $537,625. Insiders own 5.20% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of NUS. BlackRock Inc. raised its holdings in shares of Nu Skin Enterprises by 11.5% in the second quarter. BlackRock Inc. now owns 6,143,407 shares of the company’s stock valued at $480,352,000 after purchasing an additional 635,246 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its holdings in shares of Nu Skin Enterprises by 410.1% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 427,800 shares of the company’s stock valued at $35,259,000 after purchasing an additional 343,935 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Nu Skin Enterprises by 51.1% in the second quarter. Renaissance Technologies LLC now owns 814,000 shares of the company’s stock valued at $63,647,000 after purchasing an additional 275,200 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Nu Skin Enterprises by 524.5% in the third quarter. Assenagon Asset Management S.A. now owns 295,551 shares of the company’s stock valued at $24,359,000 after purchasing an additional 248,222 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Nu Skin Enterprises in the third quarter valued at approximately $12,882,000. Institutional investors own 74.66% of the company’s stock.
Nu Skin Enterprises Company Profile
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.
Further Reading: Compound Interest
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.